focus -WSS

focus

author：entertainment 2025-09-29 19:59:46 - browse：8687

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Caribou posts encouraging results on off

explore

WSS

How a Boston hospital is priming medical residents to use GPT

A new ‘biological computer' targets cancer while sparing healthy cells

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Even great ERs can’t make up for American health disparities

Vertex non

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

hotspot

focus

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Trump demands the U.S. pay no more for drugs than other countries … again

New Ultima Genomics DNA sequencer can read genome for $100

United colonoscopy coverage change 'may cost lives,' doctors say

Commercial surrogacy can be ethical, despite pope’s claims

Medicare details structure of new drug price negotiation program

Covid misinformation case heads to Supreme Court

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stanford president’s abrupt resignation sparks debate

explore

Covid misinformation case heads to Supreme Court

Covid misinformation case heads to Supreme Court

Do digital therapeutics have a future in medicine?

Judge denies Trump's request for new trial in E. Jean Carroll case

Covid misinformation case heads to Supreme Court

Caribou posts encouraging results on off

entertainment

hotspot

explore

hotspot